Smoking sucks!
Techman said:
Excellent post spin! That's exactly the way I feel. Let the bar owners decide.
If you leave it up to bar owners, we would end up with the status quo! I personally cannot wait for the new law. For all you smokers, Pfizer's new pill just got FDA approval:
UPDATE 3-US FDA approves Pfizer drug to help smokers quit
Thu May 11, 2006 4:14 PM ET
By Lisa Richwine
WASHINGTON, May 11 (Reuters) - U.S. health regulators on Thursday approved a smoking cessation pill by Pfizer Inc. <PFE.N> that helped about one-fifth of cigarette smokers quit the habit for a year in trials.
The prescription drug, Chantix, is one of several medicines the world's largest drug maker is counting on to restore earnings growth. Pfizer has forecast annual Chantix sales of $1.2 billion by 2010, but some analysts are skeptical.
Chantix works differently than older stop-smoking aids, most of which provide an alternate source of the addictive nicotine in cigarettes. The new drug targets sites in the brain affected by nicotine, the Food and Drug Administration said.
It may help smokers trying to kick the habit by providing some nicotine effects to ease withdrawal symptoms, and by blocking the effects of nicotine from cigarettes if they resume smoking, the agency said.
GlaxoSmithKline Plc's <GSK.L> <GSK.N> pill Zyban also is approved to help smokers quit, but how it works is unclear.
In two studies sponsored by Pfizer, smokers who took Chantix for 12 weeks were more likely than Zyban users to give up cigarettes. Forty-four percent of Chantix patients quit, compared with 30 percent who took Zyban.
Before treatment, the smokers had averaged 21 cigarettes a day for about 25 years.
A year later, however, there was much less difference between those who took Chantix and Zyban, although both groups fared better than placebo users, FDA officials said.
One study showed about 22 percent of Chantix users were smoke-free after a year, compared with 16 percent of Zyban users and 10 percent of those who got a placebo. A second study found no statistically meaningful difference between Zyban and Chantix users, said Dr. Curt Rosebraugh, deputy director of the FDA office that approved Chantix.
Smoking causes lung cancer, raises the risk of heart disease and contributes to other serious health problems. An estimated 44.5 million U.S. adults smoke cigarettes, and more than 8.6 million of them have at least one serious illness caused by smoking, according to government statistics.
The American Cancer Society welcomed Chantix as a new option. "But we've known for a long time that what happens in studies does not always happen in real life, so it remains to be seen whether that success rate can be maintained outside of the clinical trial environment," said Thomas Glynn, the group's director for cancer science and trends.
Nausea was the most common side effect reported, occurring in 30 percent of patients who took the maximum Chantix dose and 10 percent of placebo patients. Other side effects included headache, vomiting, flatulence, insomnia and unusual dreams.
The recommended therapy lasts 12 weeks. Patients who quit during that time can take Chantix for 12 more weeks to boost the odds of staying smoke-free, the FDA said.
The agency said it approved the drug under priority review rules that allow for quicker evaluations of medications that offer potentially significant benefits.
Chantix, known generically as varenicline, will be available in the second half of this year, Pfizer spokeswoman Shreya Prudlo said. The company has not yet set a price.
Pfizer is looking to new drugs to boost sales following a drop in demand for its painkiller Celebrex amid safety concerns and generic competition to many of its older drugs.
Some analysts questioned Pfizer's sales projections for Chantix. Bear Stearns analyst John Boris estimated about $500 million in sales in 2010, noting Glaxo had trouble convincing insurers to pay for Zyban.
Shares of New York-based Pfizer initially gained more than 1 percent after the Chantix approval but closed down nearly one percent at $24.81 on the New York Stock Exchange in a broadly lower market. (Additional reporting by Julie Vorman)